No­var­tis' CDK4/6 med Kisqali, firm­ly the sales un­der­dog against Pfiz­er's Ibrance, drops big OS da­ta

With block­buster Ibrance from Pfiz­er in its sights, No­var­tis push­ing hard to build the clin­i­cal case for CDK4/6 in­hibitor Kisqali with three years on the mar­ket. In terms of over­all sur­vival, Kisqali just dropped a ma­jor win in spe­cif­ic breast can­cer pa­tients, and it could help the drug bridge the sales gap.

Adding No­var­tis’ CDK4/6 in­hibitor Kisqali to en­docrine ther­a­py gave pre­menopausal HR-pos­i­tive, HER2-neg­a­tive breast can­cer pa­tients a me­di­an of 11 ex­tra months to live over en­docrine ther­a­py alone, mark­ing a 24% death risk re­duc­tion, ac­cord­ing to Phase III da­ta from the Monaleesa-7 tri­al un­veiled Wednes­day at the vir­tu­al San An­to­nio Breast Can­cer Sym­po­sium.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER